<![CDATA[FDA Approves Subcutaneous Isatuximab in Multiple Myeloma]]>
RegulatoryapprovedisatuximabPositive
AI Analysis
Summary
The FDA approved subcutaneous isatuximab in combination with standard of care for multiple myeloma, supported by data from the IRAKLIA trial and other studies.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
FDA approved subcutaneous isatuximab plus standard of care in multiple myeloma
Importance:8/10
Sentiment:
0.85
FDA approvalmultiple myelomasubcutaneous formulationIRAKLIA trial
Related Companies
Read the original article
Published by Cancer Network on July 10, 2026 12:45 PM